DLGAP1 antisense RNA 5 (DLGAP1-AS5)

DLGAP1 antisense RNA 5 (DLGAP1-AS5) is a long non-coding RNA (lncRNA), meaning it does not encode a protein and functions primarily at the RNA level. There is no established evidence of DLGAP1-AS5 as a therapeutic target, receptor, enzyme, or drug-interacting molecule in the literature currently[1]. By contrast, other family members such as DLGAP1 antisense RNA 1 (DLGAP1-AS1) are well-characterized and have established roles in cancer biology, acting as competing endogenous RNAs (ceRNAs) modulating miRNA activity and influencing oncogenic pathways such as JAK/STAT3 and Wnt/β-catenin in hepatocellular carcinoma, colorectal cancer, and glioma[2][3][4]. However, DLGAP1-AS5 itself is not described as having these functions and lacks evidence of being involved in disease or drug response. **Note:** DLGAP1-AS5 appears to be a rarely-discussed lncRNA, and much of the available biomedical literature instead focuses on DLGAP1-AS1, which is sometimes confused with DLGAP1-AS5. If your query intended DLGAP1-AS1, please clarify, as that molecule has robust biological and clinical evidence.

Other names

DLGAP1-AS5DLGAP1 antisense RNA 5 (non-protein coding)